Skip to content
drillr.ai
Sign up

01672.HK

Ascletis Pharma Inc.

HKSE · Healthcare · Biotechnology · CN

HKD 10.09
−2.32%
Ask drillr

  • Sep 4, 2026, 11:33 UTC

    Shanghai Stock Exchange announced adjustments to the Stock Connect southbound eligible securities, adding 54 stocks including Baidu and Ascletis Pharma, and removing 15 stocks including Youjia Innovation.

    Source:

  • Aug 31, 2026, 17:15 UTC

    Ascletis Pharma reported its interim results for the six months ended June 30, 2026, with revenue declining 48.9% year-on-year to 52.98 million RMB and net loss widening to 320 million RMB from 87.95 million RMB in the prior-year period.

    Source:

  • Aug 30, 2026, 10:15 UTC

    Ascletis announced that the first patient has been dosed in the global Phase III clinical program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management.

    Source:

  • Aug 23, 2026, 10:34 UTC

    Ascletis Pharma issued a profit warning, expecting its interim loss for the six months ending June 2026 to widen to approximately RMB 320 million, compared with RMB 88 million in the same period last year, an increase of 263.5%, mainly due to a 132.7% surge in R&D expenses to RMB 342 million.

    Source:

  • Aug 17, 2026, 08:02 UTC

    Sagimet Biosciences plans to begin a Phase III study of denifanstat for moderate-to-severe acne in the U.S. within the next several months, following positive results from a China-based Phase III trial conducted by partner Ascletis.

    Source:

  • Aug 10, 2026, 14:07 UTC

    Ascletis Pharma initiated two Phase I clinical studies in the United States for obesity treatments, including the novel amylin receptor agonist peptide ASC36 and the fixed-dose combination monthly injection ASC36_35FDC combining ASC36 with the GLP-1R/GIPR dual agonist peptide ASC35.

    Source:

  • Aug 3, 2026, 13:32 UTC

    Ascletis Pharma initiated a global Phase III clinical program for its oral small-molecule GLP-1 drug ASC30 for long-term weight management, after receiving FDA approval, enrolling about 4,600 obese or overweight subjects in the US, Europe, and Canada.

    Source:

  • Jul 28, 2026, 01:36 UTC

    Ascletis Pharma announced that its once-monthly subcutaneous triple agonist peptide ASC37 showed superior weight loss effects in a diet-induced obesity mouse model.

    Source:

  • Jul 23, 2026, 00:17 UTC

    Ascletis Pharma will present preclinical data for its obesity treatment ASC36_35 FDC at the 62nd EASD Annual Meeting in Milan, Italy.

    Source:

  • Jul 15, 2026, 09:58 UTC

    Ascletis Pharma selects fixed-dose combination of ASC48 and ASC30 for clinical development as a once-daily oral obesity therapy.

    Source:

  • Jul 6, 2026, 01:10 UTC

    Ascletis submitted two IND applications to the U.S. FDA for obesity treatments: ASC36 once-monthly injection and ASC36_35 FDC once-monthly injection.

    Source: